Tag
A phase 1b/2 study evaluating zilovertamab combined with ibrutinib in relapsed/refractory CLL reveals safety, mechanistic inhibition of ROR1 signaling pathways, and a potential efficacy signal in del(17p) patients warranting further studies
The GLOW phase III trial demonstrates that fixed-duration ibrutinib-venetoclax provides superior overall survival, progression-free survival, and safety compared to chlorambucil-obinutuzumab in older/comorbid CLL patients, with durable dise
The phase 3 SYMPATICO trial demonstrated that first-line combination therapy with ibrutinib and venetoclax yields high complete response rates and durable remissions in patients ≥65 years or with TP53 mutations suffering from nonblastoid ma
The GCLLSG CLL12 trial reveals ibrutinib’s event-free survival benefits in specific genetic subgroups of early-stage CLL, while affirming watch-and-wait as standard for high-risk patients with del(17p) and TP53 mutations.
Single-cell profiling of WM during ibrutinib therapy revealed three tumor evolution patterns, a predictive WIP score, and T-cell dysfunction linked to resistance and disease progression.
A Phase Ib study reveals that adding the anti-BAFF-R antibody ianalumab to ibrutinib therapy achieves high rates of undetectable measurable residual disease (uMRD), allowing over 40% of CLL patients to successfully discontinue long-term tre
The Phase 3 CLL17 trial demonstrates that fixed-duration venetoclax-based regimens are noninferior to continuous ibrutinib in previously untreated CLL, offering deep molecular responses and comparable progression-free survival while allowin
In the first randomized comparison of pirtobrutinib versus ibrutinib in BTKi‑naïve CLL/SLL (N=662), pirtobrutinib met noninferiority for overall response and showed favorable early PFS trends and lower rates of atrial fibrillation and hyper
The ENRICH trial demonstrates that ibrutinib combined with rituximab significantly improves progression-free survival compared to standard immunochemotherapy in older patients with untreated mantle cell lymphoma, heralding a new chemotherap
Phase 3 trial data demonstrate that ibrutinib-venetoclax therapy achieves superior undetectable measurable residual disease rates and significantly prolonged progression-free survival compared with ibrutinib alone or FCR in chronic lymphocy
A pooled analysis of prospective studies shows ibrutinib plus rituximab improves progression-free survival in Waldenström macroglobulinemia patients with CXCR4 mutations compared to ibrutinib alone, supporting routine CXCR4 testing and comb